ZM336372 | CAS#208260-29-1 | Raf-1 activating agent

MedKoo Cat#: 405650 | Name: ZM336372

Description:

WARNING: This product is for research use only, not for human or veterinary use.

ZM336372 is a Raf-1 activating agent, has been shown to cause growth inhibition and suppression of hormone secretion in a neuroendocrine cell line. ZM336372 causes growth inhibition, suppression of hormone secretion, and up-regulation of cell cycle inhibitors in a human hepatocellular carcinoma cell line, similar to that previously seen in NETs.

Chemical Structure

ZM336372

CAS#208260-29-1

Theoretical Analysis

MedKoo Cat#: 405650

Name: ZM336372

CAS#: 208260-29-1

Chemical Formula: C23H23N3O3

Exact Mass: 389.1739

Molecular Weight: 389.45

Elemental Analysis: C, 70.93; H, 5.95; N, 10.79; O, 12.32

Price and Availability

Size	Price	Availability
10mg	USD 125.00	Ready to ship
25mg	USD 250.00	Ready to ship
50mg	USD 450.00	Ready to ship
100mg	USD 750.00	Ready to ship
200mg	USD 1,350.00	Ready to ship

Bulk Inquiry

Buy Now

Add to Cart

Related CAS #

No Data

Synonym

ZM336372; ZM-336372; ZM 336372

IUPAC/Chemical Name

3-(Dimethylamino)- N -[3-[(4-hydroxybenzoyl)-amino]-4-methylphenyl]benzamide

InChi Key

PYEFPDQFAZNXLI-UHFFFAOYSA-N

InChi Code

InChI=1S/C23H23N3O3/c1-15-7-10-18(24-23(29)17-5-4-6-19(13-17)26(2)3)14-21(15)25-22(28)16-8-11-20(27)12-9-16/h4-14,27H,1-3H3,(H,24,29)(H,25,28)

SMILES Code

O=C(NC1=CC=C(C)C(NC(C2=CC=C(O)C=C2)=O)=C1)C3=CC=CC(N(C)C)=C3

Appearance

Solid powder

Purity

>98% (or refer to the Certificate of Analysis)

Shipping Condition

Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.

Storage Condition

Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).

Solubility

Soluble in DMSO, not in water

Shelf Life

>2 years if stored properly

Drug Formulation

This drug may be formulated in DMSO

Stock Solution Storage

0 - 4 C for short term (days to weeks), or -20 C for long term (months).

HS Tariff Code

2934.99.9001

More Info

Certificate of Analysis

View CoA: current batch of CoA, Lot#CRB50303

QC Data

View QC data: current batch of CoA, Lot#CRB50303

Safety Data Sheet (SDS)

View Safety Data Sheet (SDS)

Instruction

View handling instruction

Preparing Stock Solutions

The following data is based on the product molecular weight 389.45 Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.

Concentration / Solvent Volume / Mass	1 mg	5 mg	10 mg
1 mM	1.15 mL	5.76 mL	11.51 mL
5 mM	0.23 mL	1.15 mL	2.3 mL
10 mM	0.12 mL	0.58 mL	1.15 mL
50 mM	0.02 mL	0.12 mL	0.23 mL

1: Ou DL, Shen YC, Yu SL, Chen KF, Yeh PY, Fan HH, Feng WC, Wang CT, Lin LI, Hsu C, Cheng AL. Induction of DNA damage-inducible gene GADD45beta contributes to sorafenib-induced apoptosis in hepatocellular carcinoma cells. Cancer Res. 2010 Nov 15;70(22):9309-18. Epub 2010 Nov 9. PubMed PMID: 21062976. 2: Burgess S, Echeverria V. Raf inhibitors as therapeutic agents against neurodegenerative diseases. CNS Neurol Disord Drug Targets. 2010 Mar;9(1):120-7. Review. PubMed PMID: 20201822. 3: Deming D, Geiger P, Chen H, Kunnimalaiyaan M, Holen K. ZM336372 induces apoptosis associated with phosphorylation of GSK-3beta in pancreatic adenocarcinoma cell lines. J Surg Res. 2010 Jun 1;161(1):28-32. Epub 2009 Jul 12. PubMed PMID: 20031160; PubMed Central PMCID: PMC3379885. 4: Blechacz BR, Smoot RL, Bronk SF, Werneburg NW, Sirica AE, Gores GJ. Sorafenib inhibits signal transducer and activator of transcription-3 signaling in cholangiocarcinoma cells by activating the phosphatase shatterproof 2. Hepatology. 2009 Dec;50(6):1861-70. PubMed PMID: 19821497; PubMed Central PMCID: PMC2891152. 5: Echeverria V, Burgess S, Gamble-George J, Arendash GW, Citron BA. Raf inhibition protects cortical cells against beta-amyloid toxicity. Neurosci Lett. 2008 Oct 17;444(1):92-6. Epub 2008 Aug 8. PubMed PMID: 18706973. 6: Deming D, Geiger P, Chen H, Vaccaro A, Kunnimalaiyaan M, Holen K. ZM336372, a Raf-1 activator, causes suppression of proliferation in a human hepatocellular carcinoma cell line. J Gastrointest Surg. 2008 May;12(5):852-7. PubMed PMID: 18299943. 7: Kunnimalaiyaan M, Ndiaye M, Chen H. Neuroendocrine tumor cell growth inhibition by ZM336372 through alterations in multiple signaling pathways. Surgery. 2007 Dec;142(6):959-64; discussion 959-64. PubMed PMID: 18063082; PubMed Central PMCID: PMC2180346. 8: Houben R, Ortmann S, Schrama D, Herold MJ, Berberich I, Reichardt HM, Becker JC. Activation of the MAP kinase pathway induces apoptosis in the Merkel cell carcinoma cell line UISO. J Invest Dermatol. 2007 Sep;127(9):2116-22. Epub 2007 May 3. PubMed PMID: 17476292. 9: Marzec M, Kasprzycka M, Liu X, Raghunath PN, Wlodarski P, Wasik MA. Oncogenic tyrosine kinase NPM/ALK induces activation of the MEK/ERK signaling pathway independently of c-Raf. Oncogene. 2007 Feb 8;26(6):813-21. Epub 2006 Aug 7. PubMed PMID: 16909118. 10: Lai KP, Mak NK, Wei X, Wong RN, Wong MH, Wong CK. Bifunctional modulating effects of an indigo dimer (bisindigotin) to CYP1A1 induction in H4IIE cells. Toxicology. 2006 Sep 21;226(2-3):188-96. Epub 2006 Jul 4. PubMed PMID: 16901605.